[
  {
    "id": "91c99326-abbb-4f43-b784-cc15affb5b55",
    "biomarkerName": "ER (Estrogen Receptor)",
    "cancerType": "Breast Cancer",
    "positiveImplication": "Hormone receptor positive - candidate for endocrine therapy (tamoxifen, aromatase inhibitors)",
    "negativeImplication": "Hormone receptor negative - endocrine therapy not effective",
    "testingRequired": true,
    "testingMethod": "Immunohistochemistry (IHC)",
    "therapyLink": "Tamoxifen, Anastrozole, Letrozole, Fulvestrant",
    "source": "NCCN BINV v3.2025",
    "clinicalUtility": "Predicts response to endocrine therapy, required for treatment planning",
    "turnaroundTime": "2-3 days",
    "sampleRequirements": "Formalin-fixed paraffin-embedded tissue",
    "referenceLab": "Hospital pathology lab",
    "normalRange": "≥1% nuclear staining = positive",
    "criticalValues": "<1% = negative",
    "createdAt": "2025-06-30T11:49:27.002Z",
    "updatedAt": "2025-06-30T11:49:27.002Z"
  },
  {
    "id": "64921f31-7b7b-4482-8118-c30798b0807a",
    "biomarkerName": "PR (Progesterone Receptor)",
    "cancerType": "Breast Cancer",
    "positiveImplication": "Hormone receptor positive - enhanced response to endocrine therapy",
    "negativeImplication": "May still respond to endocrine therapy if ER positive",
    "testingRequired": true,
    "testingMethod": "Immunohistochemistry (IHC)",
    "therapyLink": "Combination with ER guides endocrine therapy selection",
    "source": "NCCN BINV v3.2025",
    "clinicalUtility": "Prognostic marker and predictor of endocrine therapy response",
    "turnaroundTime": "2-3 days",
    "sampleRequirements": "Formalin-fixed paraffin-embedded tissue",
    "referenceLab": "Hospital pathology lab",
    "normalRange": "≥1% nuclear staining = positive",
    "criticalValues": "<1% = negative",
    "createdAt": "2025-06-30T11:49:27.002Z",
    "updatedAt": "2025-06-30T11:49:27.002Z"
  },
  {
    "id": "6fe0f21c-c394-49e0-8f69-8baa90a426d0",
    "biomarkerName": "HER2/neu",
    "cancerType": "Breast Cancer",
    "positiveImplication": "HER2 positive (3+ IHC or FISH amplified) - candidate for HER2-targeted therapy",
    "negativeImplication": "HER2 negative - standard chemotherapy without HER2-targeted agents",
    "testingRequired": true,
    "testingMethod": "IHC followed by FISH if 2+",
    "therapyLink": "Trastuzumab, Pertuzumab, T-DM1, Trastuzumab deruxtecan",
    "source": "NCCN BINV v3.2025",
    "clinicalUtility": "Predicts response to HER2-targeted therapy, required for treatment selection",
    "turnaroundTime": "5-7 days",
    "sampleRequirements": "Fresh or FFPE tissue",
    "referenceLab": "Reference laboratory for FISH",
    "normalRange": "IHC: 0-1+ negative, 3+ positive, 2+ requires FISH",
    "criticalValues": "FISH: HER2/CEP17 ratio ≥2.0 = amplified",
    "createdAt": "2025-06-30T11:49:27.002Z",
    "updatedAt": "2025-06-30T11:49:27.002Z"
  },
  {
    "id": "6626bb9c-bc94-4452-98a4-c50ef1b4a13e",
    "biomarkerName": "EGFR mutation",
    "cancerType": "Lung Cancer",
    "positiveImplication": "EGFR mutated - first-line EGFR TKI therapy (osimertinib preferred)",
    "negativeImplication": "EGFR wild-type - immunotherapy or chemotherapy based on PD-L1",
    "testingRequired": true,
    "testingMethod": "Next-generation sequencing (NGS)",
    "therapyLink": "Osimertinib, Erlotinib, Gefitinib, Afatinib",
    "source": "NCCN NSCLC v5.2025",
    "clinicalUtility": "Predictive biomarker for EGFR TKI response, especially exon 19 del and L858R",
    "turnaroundTime": "7-10 days",
    "sampleRequirements": "Tissue or liquid biopsy (ctDNA)",
    "referenceLab": "Molecular pathology lab",
    "normalRange": "Wild-type = no actionable mutations",
    "criticalValues": "Exon 19 deletion, L858R, T790M resistance mutation",
    "createdAt": "2025-06-30T11:49:27.002Z",
    "updatedAt": "2025-06-30T11:49:27.002Z"
  },
  {
    "id": "5e19896e-a298-449c-bcf7-4f689529382a",
    "biomarkerName": "ALK rearrangement",
    "cancerType": "Lung Cancer",
    "positiveImplication": "ALK positive - first-line ALK inhibitor therapy",
    "negativeImplication": "ALK negative - standard therapy based on other biomarkers",
    "testingRequired": true,
    "testingMethod": "FISH or IHC with NGS confirmation",
    "therapyLink": "Alectinib, Brigatinib, Lorlatinib, Crizotinib",
    "source": "NCCN NSCLC v5.2025",
    "clinicalUtility": "Predictive biomarker for ALK inhibitor response",
    "turnaroundTime": "5-7 days",
    "sampleRequirements": "Formalin-fixed paraffin-embedded tissue",
    "referenceLab": "Reference molecular lab",
    "normalRange": "No rearrangement detected",
    "criticalValues": "EML4-ALK fusion variants",
    "createdAt": "2025-06-30T11:49:27.002Z",
    "updatedAt": "2025-06-30T11:49:27.002Z"
  },
  {
    "id": "eeb74a17-9cdd-46e5-9370-b41f258bb497",
    "biomarkerName": "PD-L1 expression",
    "cancerType": "Lung Cancer",
    "positiveImplication": "High expression (≥50%) - first-line immunotherapy monotherapy consideration",
    "negativeImplication": "Low/negative expression - combination therapy preferred",
    "testingRequired": true,
    "testingMethod": "Immunohistochemistry (22C3 antibody)",
    "therapyLink": "Pembrolizumab, Nivolumab, Atezolizumab",
    "source": "NCCN NSCLC v5.2025",
    "clinicalUtility": "Predictive biomarker for immune checkpoint inhibitor response",
    "turnaroundTime": "3-5 days",
    "sampleRequirements": "Fresh tissue preferred, FFPE acceptable",
    "referenceLab": "Hospital immunohistochemistry lab",
    "normalRange": "0% = negative",
    "criticalValues": "≥50% = high expression, 1-49% = low expression",
    "createdAt": "2025-06-30T11:49:27.002Z",
    "updatedAt": "2025-06-30T11:49:27.002Z"
  },
  {
    "id": "d1dbfab6-6b45-47cb-9a84-cc130f843d72",
    "biomarkerName": "KRAS/NRAS mutation",
    "cancerType": "Colorectal Cancer",
    "positiveImplication": "KRAS/NRAS mutated - anti-EGFR therapy contraindicated",
    "negativeImplication": "KRAS/NRAS wild-type - candidate for anti-EGFR therapy (cetuximab, panitumumab)",
    "testingRequired": true,
    "testingMethod": "Next-generation sequencing or PCR",
    "therapyLink": "Excludes anti-EGFR therapy if mutated",
    "source": "NCCN Colon v3.2025",
    "clinicalUtility": "Predictive biomarker for anti-EGFR therapy resistance",
    "turnaroundTime": "5-7 days",
    "sampleRequirements": "Tumor tissue from primary or metastatic site",
    "referenceLab": "Molecular pathology laboratory",
    "normalRange": "Wild-type = no mutations detected",
    "criticalValues": "Codon 12, 13, 61, 117, 146 mutations",
    "createdAt": "2025-06-30T11:49:27.002Z",
    "updatedAt": "2025-06-30T11:49:27.002Z"
  },
  {
    "id": "544feb66-229b-4d6d-89c3-da1b8bb31202",
    "biomarkerName": "BRAF V600E mutation",
    "cancerType": "Colorectal Cancer",
    "positiveImplication": "BRAF mutated - poor prognosis, consider BRAF-targeted therapy combinations",
    "negativeImplication": "BRAF wild-type - standard therapy options apply",
    "testingRequired": true,
    "testingMethod": "Next-generation sequencing or PCR",
    "therapyLink": "Encorafenib + cetuximab + binimetinib combination",
    "source": "NCCN Colon v3.2025",
    "clinicalUtility": "Prognostic and predictive biomarker, associated with poor prognosis",
    "turnaroundTime": "5-7 days",
    "sampleRequirements": "Formalin-fixed paraffin-embedded tissue",
    "referenceLab": "Molecular pathology laboratory",
    "normalRange": "Wild-type = no V600E mutation",
    "criticalValues": "V600E mutation detected",
    "createdAt": "2025-06-30T11:49:27.002Z",
    "updatedAt": "2025-06-30T11:49:27.002Z"
  },
  {
    "id": "098092cf-7c65-479b-843c-812470223cc8",
    "biomarkerName": "MSI/MMR status",
    "cancerType": "Colorectal Cancer",
    "positiveImplication": "MSI-H/dMMR - candidate for immunotherapy (pembrolizumab)",
    "negativeImplication": "MSS/pMMR - standard chemotherapy without immunotherapy",
    "testingRequired": true,
    "testingMethod": "IHC for MMR proteins + MSI testing",
    "therapyLink": "Pembrolizumab, Nivolumab + ipilimumab",
    "source": "NCCN Colon v3.2025",
    "clinicalUtility": "Predictive biomarker for immune checkpoint inhibitor response",
    "turnaroundTime": "5-7 days",
    "sampleRequirements": "Tumor tissue",
    "referenceLab": "Molecular pathology laboratory",
    "normalRange": "MSS = microsatellite stable",
    "criticalValues": "MSI-H = high microsatellite instability",
    "createdAt": "2025-06-30T11:49:27.002Z",
    "updatedAt": "2025-06-30T11:49:27.002Z"
  },
  {
    "id": "f2c20c92-0076-4c97-b60a-485c98c83f67",
    "biomarkerName": "Gleason Score",
    "cancerType": "Prostate Cancer",
    "positiveImplication": "Gleason ≥8 - high-grade, aggressive disease requiring multimodal therapy",
    "negativeImplication": "Gleason ≤6 - low-grade, consider active surveillance",
    "testingRequired": true,
    "testingMethod": "Histopathological grading",
    "therapyLink": "Risk stratification guides treatment intensity",
    "source": "NCCN Prostate v4.2025",
    "clinicalUtility": "Primary prognostic factor for treatment planning",
    "turnaroundTime": "3-5 days",
    "sampleRequirements": "Prostate biopsy cores",
    "referenceLab": "Hospital pathology department",
    "normalRange": "Gleason 3+3=6 (low grade)",
    "criticalValues": "Gleason 4+4=8 or higher (high grade)",
    "createdAt": "2025-06-30T11:49:27.002Z",
    "updatedAt": "2025-06-30T11:49:27.002Z"
  }
]